Haloperidol

  • 4-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-4'-Fluorobutyrophenone
  • Aloperidin
  • Aloperidolo
  • Aloperidon
  • gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-Fluorbutyrophenone
Formula
C21H23ClFNO2
Structure
Description
Clear, colorless solution with no odor.
Uses
Medication (vet).

Registry Numbers and Inventories.
CAS
52-86-8
EC (EINECS/ELINCS)
200-155-6
RTECS
EU1575000
RTECS class
Tumorigen; Drug; Mutagen; Reproductive Effector; Human Data
Merck
12,4629
Beilstein/Gmelin
331267
Beilstein Reference
5-21-02-00377
Austrailia AICS
Listed
New Zealand
Listed
Japan ENCS (MITI)
Listed
Korea ECL
Listed

Properties.
Formula
C21H23ClFNO2
Formula mass
375.87
Melting point, °C
147
Boiling point, °C
529
Vapor pressure, mmHg
5E-12 (25 C)
Density
1.3 g/cm3 (20 C)
Solubility in water
14 mg/L
pKa/pKb
5.75 (pKb)
Partition coefficient, pKow
3.36
Heat of fusion
48.0 kJ/mol
Heat of vaporization
84.6 kJ/mol

Hazards and Protection.
Storage
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Latex gloves, safety goggles, disposable protective apparel.
Respirators
NIOSH approved respirator.
Small spills/leaks
Wear recommended protective equipment. Sweep up material or absorb with paper towels. Place in appropriate container for disposal.
Stability
Stable at normal temperature and pressure.

Fire.
Flash Point,°C
274
Fire fighting
Wear SCBA and protective clothing. Use extinguishing media most appropriate for surrounding fire.

Health.
Exposure effects
Abnormally low blood pressure may develop in adults and children who have ingested an overdose of haloperidol. One pediatric case of elevated blood pressure following overdose has been reported. Elevated body temperature has both been associated with haloperidol therapy and may occur with overdose. Respiratory depression may occur. haloperidol - severe extrapyramidal effects may follow overdose. Irreversible tardive dyskinesia has been reported with therapeutic use and may occur with overdose. Seizures have been reported with pediatric overdose. Neuroleptic malignant syndrome has been rarely reported in adults and children. Droperidol - extrapyramidal effects have been reported following droperidol therapy. Neuroleptic malignant syndrome has been reported in adults and children.

First aid
 
   Ingestion
Wash mouth out with water. Seek medical aid.
   Inhalation
Remove to fresh air. Seek medical aid.
   Skin
Flush skin with water. Seek medical aid.
   Eyes
Flush eyes with water. Seek medical aid.

Transport.